To evaluate implementation of the Dana-Farber Cancer Institute (DFCI) carboplatin allocation plan and assess whether clinical or demographic factors not included in its criteria were associated with allocation decisions.
Approach:
Design: Retrospective cohort study of DFCI’s carboplatin shortage management.
Policy: From June 1 through July 17, 2023, a multidisciplinary working group assigned patients priority categories 1–5. The policy intended categories 1–3 to receive carboplatin and categories 4–5 not to receive it.
Evaluation: Researchers compared documented allocation decisions with decisions implied by recorded priority categories and with categories and decisions assigned through independent medical-record review. They also assessed associations between patient characteristics an…
Key Findings:
The supplied context describes the study objectives, policy, and evaluation methods but does not provide study results.
Interpretation:
The study was designed to assess consistency in applying the allocation plan and whether allocation was associated with factors beyond the stated criteria; findings are not included in the supplied context.
Limitations:
The provided article context ends before the results and does not report the cohort size, measured associations, or implementation findings.
Breast cancer screening has traditionally been organized around two principal variables: when mammography should begin and how frequently it should be performed.
